BRIDGEWATER, N.J., March 13 /PRNewswire-FirstCall/ -- Spring is in the air and for the millions of children suffering from seasonal allergies each year, and their parents, managing symptoms of the condition is important. Studies indicate that seasonal allergy symptoms as well as the impairing side effects of older antihistamines can be disruptive to a child. New Allegra(R) (fexofenadine hydrochloride) Oral Suspension is available for the treatment of symptoms associated with seasonal allergies in pediatric patients 2 through 11 years of age without making children drowsy or causing impairment. Symptoms of seasonal allergies include runny nose, sneezing, watery eyes and itchy nose, eyes and throat.
“As the spring allergy season approaches, parents should be aware of the symptoms as well as safe and effective available treatments for their children,” said Eli Meltzer, M.D., of the Allergy and Asthma Medical Group and Research Center in San Diego. “The new Allegra Oral Suspension is a treatment option that parents can trust to safely and effectively minimize the child’s symptoms during their daily activities.”
Allegra Oral Suspension is berry-flavored* and designed with children in mind. It also treats hives which are caused by a reaction to an unknown trigger in the upper layers of the skin. The condition itself usually lasts more than six weeks and may cause severe itching that is made worse by scratching.
Allegra Oral Suspension was approved by the U.S. Food and Drug Administration in October 2006, for the twice-daily treatment of seasonal allergy symptoms in children, ages 2 through 11 years, and for the treatment of chronic hives in children, ages 6 months through 11 years.
Important Safety Information
Side effects with Allegra Oral Suspension 30 mg/5 mL (6 mg/mL) are low and may include vomiting, fever, cough, ear infection or diarrhea.
Please see full prescribing information for Allegra Oral Suspension at http://www.allegra.com/docs/pdf/AOS_PI.pdf
*Artificial raspberry-cream flavoring.
About sanofi-aventis
Sanofi-aventis is one of the world’s leading pharmaceutical companies. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular, thrombosis, oncology, metabolic diseases, central nervous system, internal medicine and vaccines. Sanofi-aventis is listed in Paris and in New York .
U.S. Contact: Emmy Tsui, 908-981-6573, emmy.tsui@sanofi-aventis.com
US.AOS.07.02.011
sanofi-aventis
CONTACT: Emmy Tsui, +1-908-981-6573, emmy.tsui@sanofi-aventis.com
Company News On-Call: http://www.prnewswire.com/comp/232375.html /
